MP
BIOS

Mangrove Partners’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Mangrove Partners’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-405,141
Closed -$4.03M – 514
2022
Q2 		$4.03M Buy
+405,141
New +$4.02M 0.2% 214

Other funds holding BIOS

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
SV
Starboard Value New York $4.52B AUM 19.34% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Mangrove Partners's BIOS Position: Q3 2022 in Review

Mangrove Partners sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q3 2022, closing a stake of 405,141 shares — an estimated $4.03M sold.

Mangrove Partners first reported a position in BIOS in Q2 2022 and held it in 1 quarter. The position peaked at $4.03M in Q2 2022. 67 funds tracked by Wall St. Rank hold BIOS as of Q3 2022.

  • Mangrove Partners reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 405,141 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q3 2022, an estimated $4.03M.
  • Mangrove Partners first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q2 2022 and held it in 1 quarter.
  • Mangrove Partners's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $4.03M in Q2 2022.
  • 67 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.